Presented: Poster - Tuesday, November 13, 2012, 8:00 am
What Patients Need to Know about Acetaminophen
The misuse of acetaminophen is the leading cause of acute liver failure in
the West. Informed patients and clearly labeled prescription bottles are
necessary to avoid accidental overdoses. Patients with new prescriptions often
are unaware of the presence of acetaminophen in their new drug nor do they
recall their prescribers’ advice concerning acetaminophen, according to
researchers at Northwestern University who examined the behavior of 249 patients
who were either discharged from a hospital emergency room or recently visited an
outpatient pharmacy.
Only 25.7 percent of patients could recall counseling concerning
acetaminophen from their prescribers. According to Dr. Marina Serper of The
Health Literacy and Learning Program at Northwestern University, “When
prescribing an acetaminophen-containing medication, healthcare providers should
clearly state the active ingredients in the medication. Providers should explain
what constitutes the daily maximum dose of this medication and how it may or may
not be combined with other common over the counter acetaminophen
preparations.”
Researchers asked patients to keep a diary of the medications they had taken
in the first seven days after starting their new prescription. All patients were
interviewed after seven days to determine the presence of warning labels on
bottles, the total amount and sources of acetaminophen taken, patients’
knowledge of active ingredients in prescriptions, and patient recall of any
communication concerning acetaminophen with the prescriber.
The study also addressed what Dr. Serper refers to as, “the lack of
uniformity of prescription labeling.” Only 26.9 percent of patients studied
correctly identified acetaminophen as an ingredient in their prescription
medication. Researchers reported 10.8 percent of those patients studied
“double-dipped,” meaning that they took their new prescription along with
another product containing acetaminophen on the same day – most often an over
the counter pain medication.
Four of the 249 patients (1.6 percent) exceeded the recommended daily dose of
4 grams. “In our anecdotal experience, patients do not always understand the
meaning of 4000 mg or 4 g and it is more helpful to say something like, ‘you
should not take more than 8 pills of this medication per day’”, said Dr.
Serper.
Compounding the confusion was that acetaminophen was identified by one of two
abbreviations (APAP or ACET) on the prescription label 87.3 percent of the time,
and only 59 percent of those prescription bottles had an acetaminophen warning.
Dr. Serper addressed this point, “It is equally and perhaps more important to
have clear and universal labeling of acetaminophen on prescription bottles,
something which does not routinely occur, as shown by our study.”
The general confusion faced by patients who are unaware of the active
ingredients in their prescription medication because of insufficient or
inconsistent labeling of ingredients and warnings, as well as insufficient
counseling by prescribers, can put patients in danger of exceeding the daily
recommended dose of acetaminophen which can lead to acute liver failure.
Researchers concluded that the elimination of abbreviations on prescription
labels and more consistent verbal counseling from healthcare providers was
needed to minimize this danger.
Abstract
title:
Active Ingredient Confusion for Acetaminophen-Containing
Medications: A Cause of Double Dipping
###
AASLD is the leading medical organization for advancing the science and
practice of hepatology. Founded by physicians in 1950, AASLD's vision is to
prevent and cure liver diseases. This year's Liver Meeting®, held in Boston,
Massachusetts November 9 – 13, will bring together more than 9,000 researchers
from 55 countries.
A pressroom will be available from November 10 at the annual meeting. For
copies of abstracts and press releases, or to arrange researcher interviews,
contact Gregory Bologna at 703-299-9766.
http://www.aasld.org/lm2012/2012/press/Pages/acetaminophen.aspx
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment